中期随访比较翻修与初次骨软骨同种异体移植:患者报告结局、移植物存活率与再手术率
回顾性队列研究纳入1999至2018年股骨髁翻修骨软骨同种异体移植15例,按缺损大小、年龄、性别和体重指数1:2匹配30例初次移植患者,最少随访5年。翻修组多数患者达到患者可接受症状状态,再手术率53%,失败率20%,移植物无失败存活率与初次移植组无显著差异。
要点
- 翻修骨软骨同种异体移植后多数患者达到患者可接受症状状态,各指标70%至100%不等。
- 翻修组再手术率53%,失败率20%,移植物无再手术和无失败存活率与初次组无显著差异。
- 研究样本量有限,作者指出无失败存活率差异不显著受样本量限制。
核心结论
- 翻修骨软骨同种异体移植后观察到较高的患者可接受症状状态达成率。
- 尽管受样本量限制,翻修与初次骨软骨同种异体移植组间移植物无失败存活率未见显著差异。
研究设计与样本
- 队列研究,证据等级3级。
- 回顾性分析前瞻性收集的数据,识别1999至2018年间接受股骨髁翻修骨软骨同种异体移植且最少随访5年的患者。
- 按缺损大小、年龄、性别和体重指数1:2匹配,创建翻修组与初次骨软骨同种异体移植组的匹配队列。
- 翻修组15例匹配初次组30例;翻修组平均随访9.3±3.0年(范围5.1-14.7年),平均年龄31.4±10.0岁(范围19.9-52.7岁),平均体重指数25.9±3.4(范围20.8-30.4)。
- 失败定义为经二次探查关节镜确认的骨软骨同种异体移植软骨下塌陷、翻修骨软骨同种异体移植或转为膝关节置换。
主要发现
- 翻修骨软骨同种异体移植至外侧髁占53%(8/15);73%(11/15)患者行伴随手术,最常见为半月板同种异体移植(73%[8/11]),其次为力线矫正截骨(27%[3/11])。
- 翻修组达到患者可接受症状状态的比例:国际膝关节文献委员会(IKDC)70%、Lysholm 83%、膝关节损伤和骨关节炎结局评分(KOOS)疼痛100%、KOOS症状70%、KOOS运动90%、KOOS日常生活活动80%、KOOS生活质量80%。
- 翻修组与初次组达到患者可接受症状状态的比例无差异(P≥0.070)(见表3)。
- 翻修组8例(53%)行再手术,平均时间3.9±3.7年(范围0.6-11.2年);翻修组失败3例(20%),平均时间4.3±1.9年(范围1.7-6.4年)。
- 移植物无再手术存活率(P=0.905;翻修组53%[8/15] vs 初次组43%[13/30])和无失败存活率(P=0.577;翻修组13%[2/15] vs 初次组20%[6/30])在翻修与初次组间无显著差异。
关键数值与推荐
- 失败定义为经二次探查关节镜确认的骨软骨同种异体移植软骨下塌陷、翻修骨软骨同种异体移植或转为膝关节置换。
- 翻修组达到患者可接受症状状态的比例:IKDC 70%、Lysholm 83%、KOOS疼痛100%、KOOS症状70%、KOOS运动90%、KOOS日常生活活动80%、KOOS生活质量80%。
- 翻修组与初次组达到患者可接受症状状态的比例比较P≥0.070。
- 移植物无再手术存活率比较P=0.905(翻修组53%[8/15] vs 初次组43%[13/30])。
- 移植物无失败存活率比较P=0.577(翻修组13%[2/15] vs 初次组20%[6/30])。
局限性
- 作者指出研究受样本量限制,翻修与初次骨软骨同种异体移植组间移植物无失败存活率未见显著差异这一结果受此限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have observed promising short-term outcomes after revision osteochondral allograft (OCA) transplantation. However, few studies have examined midterm outcomes after revision OCA transplantation. PURPOSE: To examine midterm outcomes after revision OCA transplantation of the femoral condyle and evaluate reoperation and survivorship compared with a matched cohort of patients who underwent primary OCA transplantation. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A retrospective review of prospectively collected data identified patients undergoing revision OCA transplantation to the femoral condyle between 1999 and 2018 (minimum 5-year follow-up). A 1:2 cohort of patients who underwent revision OCA transplantation to patients who underwent primary OCA transplantation, matched by defect size, age, sex, and body mass index, was created. Patient-reported outcome measures and the incidence of reoperations or graft failures were collected. Failure was defined as subchondral collapse of the OCA transplantation as confirmed via second-look arthroscopy, revision OCA transplantation, or conversion to knee arthroplasty. RESULTS: Fifteen patients who underwent revision OCA transplantation were matched to 30 patients who underwent primary OCA transplantation. The mean follow-up in the revision OCA transplantation group was 9.3 ± 3.0 years (range, 5.1-14.7 years), with a mean age of 31.4 ± 10.0 years (range, 19.9-52.7 years) and a mean body mass index of 25.9 ± 3.4 (range, 20.8-30.4). Revision OCA transplantation was performed to the lateral condyle in 53% of cases (8/15). A concomitant procedure was performed in 73% of patients (11/15), most commonly involving meniscal allograft transplantation (73% [8/11]), followed by realignment osteotomy (27% [3/11]). The Patient Acceptable Symptom State was achieved by a majority of patients who underwent revision OCA transplantation for all patient-reported outcome measures examined (International Knee Documentation Committee, 70%; Lysholm, 83%; Knee injury and Osteoarthritis Outcome Score [KOOS] Pain, 100%; KOOS Symptoms, 70%, KOOS Sport, 90%; KOOS Activities of Daily Living, 80%; KOOS Quality of Life, 80%), and there was no difference in the proportion of patients the Patient Acceptable Symptom State when compared with those undergoing primary OCA transplantation (P≥ .070) (see Table 3). Eight patients (53%) underwent revision OCA transplantation reoperation at a mean time of 3.9 ± 3.7 years (range, 0.6-11.2 years). Failures were observed in 20% (3/15) of patients who underwent revision OCA transplantation at a mean of 4.3 ± 1.9 years (range, 1.7-6.4 years). Graft survivorship free from reoperation (P = .905; revision 53% [8/15], primary 43% [13/30]) and failure (P = .577; revision 13% [2/15], primary 20% [6/30]) was not significantly different between revision and primary groups. CONCLUSION: High rates of Patient Acceptable Symptom State achievement were observed after revision OCA transplantation. Although limited by sample size, no significant difference in graft survivorship free from failure was appreciated between revision versus primary OCA transplantation groups.
引用
- Meeker ZD, Knapik DM, Wagner KR, et al. Comparison of Revision and Primary Osteochondral Allograft Transplantation at Midterm Follow-up: Patient Reported Outcomes, Survivorship, and Reoperation Rates. Am J Sports Med. 2025. PMID: 39972524. doi:10.1177/03635465251316475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。